Hearing diabetes in a one-minute electrocardiogram: Why phenotype-stratified machine learning may outperform one-size-fits-all screening

Abstract

Undiagnosed diabetes mellitus (DM) remains common, and scalable screening approaches that can be deployed beyond laboratory testing are urgently needed. In the recent issue of World Journal of Cardiology, Karbovskaya et al report a machine learning strategy to detect DM from a one-minute, single-lead electrocardiogram (ECG) acquired with a portable device in 629 participants, addressing a central barrier to ECG-based DM detection: Confounding by coexisting cardiovascular disease (CVD). Rather than treating the population as homogeneous, the investigators used phenotypic clustering of clinical profiles and a cluster-stratified validation scheme (training on three clusters and testing on the fourth) to identify where DM-specific ECG signatures are most discernible. Performance concentrated in a comorbidity-burdened, high-DM phenotype (cluster 4), with sensitivity 75%, specificity 83%, and area under the curve 0.88, suggesting that “precision screening” may be a more realistic paradigm than universal classifiers. This editorial highlights the study’s key contribution, explicitly modeling phenotype to mitigate CVD confounding, while emphasizing the translational prerequisites for impact: External, multi-center validation; assessment of calibration and workflow utility; and careful attention to device-specific, proprietary feature extraction and modest cluster sizes that may limit portability. If replicated, phenotype-targeted single-lead ECG could serve as a low-cost triage tool to trigger confirmatory glycemic testing in high-risk settings.

Key Words: Diabetes mellitus; Machine learning; Electrocardiography; Digital biomarkers; Single-lead electrocardiogram

Core Tip: A one-minute, single-lead electrocardiogram (ECG) may enable scalable screening for diabetes mellitus (DM) when paired with machine learning. Karbovskaya et al introduced a phenotype-clustering strategy that explicitly accounts for clinical heterogeneity and cardiovascular comorbidity, revealing that DM-related ECG signatures are most detectable in specific patient subgroups rather than uniformly across populations. By emphasizing interpretable electrophysiologic features and testing model transportability across phenotypes, this work advances a “precision screening” paradigm and provides a practical roadmap for translating ECG-based metabolic risk detection into real-world cardiometabolic workflows.

This editorial refers to “Machine learning-based detection of diabetes mellitus from single-lead electrocardiography: A phenotype-stratified approach” by Karbovskaya et al, 2026; https://doi.org/10.4330/wjc.v18.i3.116217.

---

INTRODUCTION

Diabetes mellitus (DM) is a leading driver of cardiovascular morbidity and premature mortality, yet a substantial fraction of individuals remains unaware of their condition until complications emerge. Recent global estimates underscore the scale of the problem, with prevalence continuing to rise and projections indicating sustained growth over the coming decades[1,2]. Because early identification and treatment reduce microvascular and macrovascular complications, professional societies and public health bodies emphasize periodic screening and risk-based case finding using laboratory measures such as fasting plasma glucose and glycated hemoglobin (HbA1c)[3-5]. However, laboratory-first strategies face persistent implementation barriers, limited access, cost, low uptake, and the reality that screening often misses individuals who rarely engage in preventive care. These gaps motivate interest in passive or opportunistic screening tools that are inexpensive, non-invasive, and deployable on a scale.

ELECTROCARDIOGRAPHY AS A METABOLIC SENSOR

The electrocardiogram (ECG) is among the most widely performed tests in medicine, and its potential role is expanding beyond traditional rhythm and ischemia assessment. A growing body of work suggests that systemic metabolic derangements, including dysglycemia, leave subtle but detectable fingerprints on cardiac electrophysiology. Prior studies have reported that diabetes and hyperglycemia may be associated with repolarization changes such as prolonged QT or corrected QT intervals, greater QT dispersion, and altered T-wave morphology (e.g., flattening, asymmetry, or nonspecific ST-T changes)[6-8], alongside autonomic tone alterations reflected in heart rate variability and subtle conduction differences. These markers are not specific for diabetes and can be influenced by medications, electrolyte disturbances, ischemia, and structural heart disease; therefore, they are most informative when modeled jointly rather than interpreted in isolation. These observations have spurred data-driven approaches that use ECG-derived features or deep learning models to detect hyperglycemia, diabetes, or prediabetes from standard ECGs[9-15]. Importantly, the proliferation of consumer wearables and smartphone-enabled devices has made single-lead ECG acquisition feasible outside clinical environments, raising the possibility of low-friction population screening[16,17].

WHAT IS NEW IN THE STUDY BY KARBOVSKAYA ET AL

In the recent issue of World Journal of Cardiology, Karbovskaya et al[18] propose an interpretable machine-learning pipeline to classify DM from a one-minute single-lead ECG recording collected with a portable device, using a modest set of device-derived ECG parameters, such as average heart rate and R-R interval variability, QRS complex duration, QT interval and corrected QT intervals, ST segment level or slope measures, and T-wave amplitude/shape indices, computed by the device’s analysis software. The study’s methodological contribution is not only the classifier itself, but the decision to explicitly model clinical heterogeneity via phenotype clustering. Using echocardiographic and clinical variables, the authors grouped participants into four phenotypic clusters spanning a spectrum from lower-risk profiles to more comorbidity-enriched cardiovascular phenotypes. They then trained models on three clusters and evaluated performance on the withheld cluster, an approach that resembles a pragmatic stress test for domain shift and encourages attention to generalizability. Across clusters, performance ranged from near-excellent discrimination to substantially weaker results, reinforcing the core message that “one-size-fits-all” ECG screening may fail when underlying phenotype distributions differ.

PHENOTYPE CLUSTERING: A PRACTICAL RESPONSE TO CLINICAL HETEROGENEITY

Clinical prediction models often degrade when transported across settings because patient populations differ in age, comorbidity burden, treatment patterns, and measurement devices. In ECG-based metabolic screening, heterogeneity is especially consequential: Cardiovascular disease and its therapies can alter ECG morphology in ways that compete with, mask, or mimic the electrophysiologic effects of diabetes. Phenotype clustering offers a pragmatic strategy to reduce this “spectrum bias” by stratifying model development and evaluation across clinically coherent subgroups. In the work by Karbovskaya et al[18], the cluster with the most clinically promising performance represented individuals with substantial cardiometabolic risk burden yet preserved systolic function, suggesting an operational window where diabetes-related repolarization and conduction signatures remain discernible before advanced structural disease dominates the signal. This concept mirrors broader lessons from applied machine learning: Robust clinical tools are often those that explicitly anticipate domain shift rather than assuming identical data-generating processes across patient strata[19-21].

INTERPRETABILITY AND BIOLOGICAL PLAUSIBILITY MATTER FOR TRANSLATION

A frequent critique of artificial intelligence (AI)-enabled diagnostics is limited interpretability[22,23]. While black-box performance may be acceptable in low-stakes consumer applications, clinical adoption depends on trust, explainability, and the ability to probe failure modes. The current study’s reliance on a curated set of ECG descriptors, highlighting repolarization and conduction-related markers, supports mechanistic plausibility. For example, repolarization heterogeneity has been linked to adverse outcomes and may reflect myocardial substrate changes that can be influenced by metabolic disease[24]. Similarly, low-amplitude or “flat” T-wave morphologies have been associated with cardiovascular risk in population studies[25]. Although such markers are not specific to diabetes, their consistent selection by feature-importance analysis strengthens the argument that the model is leveraging physiologically meaningful patterns rather than exploiting spurious correlations.

FROM DISCRIMINATION TO CLINICAL UTILITY: WHAT COMES NEXT

High area under the receiver operating characteristic curve values are encouraging, but translation requires additional evidence that the model improves care. First, calibration should be assessed: A well-calibrated model produces risk estimates that correspond to observed probabilities, which is essential when using predictions to trigger confirmatory testing. Second, performance should be evaluated across clinically relevant prevalence settings, because positive and negative predictive values vary with baseline risk. Third, real-world utility will hinge on an actionable workflow, such as using ECG-based screening to flag individuals for HbA1c testing in cardiology clinics, emergency departments, or community screening events. Finally, given the rapid evolution of reporting and quality standards for prediction models, future studies should follow the Transparent Reporting of a multivariable prediction model of Individual Prognosis Or Diagnosis (TRIPOD) + AI reporting guidance and use structured risk-of-bias appraisal such as the Prediction model Risk of Bias Assessment Tool (PROBAST)/PROBAST + AI to promote transparency and reproducibility[26-29]. Key translational checkpoints for deployment are summarized in Table 1.

Table 1 Translational considerations for phenotype-aware single-lead electrocardiogram screening of diabetes mellitus.

Domain	Key question	Practical recommendation
Cohort design	Is the training cohort representative of the target screening population?	Include multi-site data; report phenotype distributions; avoid convenience-only sampling
Phenotype heterogeneity	Does performance vary across cardiovascular phenotypes and comorbidity burden?	Use phenotype clustering or stratified analyses; consider phenotype-specific thresholds
Device generalizability	Will the model transport across single-lead devices and preprocessing pipelines?	Validate across hardware/software stacks; quantify performance drift; standardize signal processing when feasible
Model validity	Is discrimination and calibration adequate for case-finding?	Report area under the receiver operating characteristic curve plus calibration; provide decision curves; justify threshold selection by clinical workflow
Equity and bias	Are error rates consistent across sex, age, and racial/ethnic subgroups?	Pre-specify subgroup analyses; rebalance training; assesses fairness metrics; monitor post-deployment
Clinical workflow	How will predictions trigger confirmatory testing and follow-up?	Define a triage pathway (electrocardiogram flag → glycated hemoglobin or fasting glucose → counseling/treatment)
Reporting and quality	Is the work transparent and reproducible?	Follow TRIPOD + AI; assess with PROBAST/PROBAST + AI; share code, model cards, and validation plans when possible

AI: Artificial intelligence; TRIPOD: Transparent Reporting of a multivariable prediction model of Individual Prognosis or Diagnosis; PROBAST: Prediction model Risk of Bias Assessment Tool.

LIMITATIONS AND IMPLEMENTATION CHALLENGES

Several challenges warrant attention before single-lead ECG screening for diabetes can be deployed broadly. Device dependence is an immediate concern: Models trained on one hardware/software stack may not transport to other single-lead devices with different sampling rates, filters, or measurement algorithms. External validation across devices, healthcare systems, and geographic regions is therefore essential. Equity is another key issue: ECG algorithms can exhibit differential performance across demographic groups when training data are imbalanced or when physiological correlations differ by ancestry and comorbidity patterns. Prospective studies should pre-specify subgroup analyses and consider mitigation strategies (reweighting, stratified thresholds, or multi-task learning) to avoid widening disparities. Finally, diabetes screening is a high-volume use case; false positives can drive unnecessary testing, while false negatives may provide unwarranted reassurance. Careful selection of operating thresholds, potentially tuned to maximize sensitivity for case-finding, and clear communication that ECG screening does not replace diagnostic laboratory testing will be critical. Beyond model performance, successful roll-out requires organizational investment: Governance for clinical decision support, staff training, clear ownership for monitoring and recalibration, and pathways for confirmatory testing and follow-up that fit local clinic workflows.

ROADMAP FOR PHENOTYPE-AWARE ECG SCREENING

The conceptual advances in the study by Karbovskaya et al[18] suggest a roadmap for the next phase of research. First, replicate the phenotype-aware approach in larger multi-center datasets that include diverse age, sex, and racial/ethnic distributions. Second, transition from cross-sectional classification to longitudinal prediction (e.g., incident diabetes or progression from prediabetes), which may align more closely with preventive cardiometabolic care, as seen in recent deep learning ECG risk work[30-32]. Third, evaluate hybrid models that combine ECG features with simple non-invasive covariates (age, body mass index, blood pressure) to improve robustness while retaining scalability. Finally, embed the tool into pragmatic trials that measure clinical endpoints: Screening uptake, time to diagnosis, initiation of lifestyle or pharmacologic prevention, and downstream cardiovascular outcomes.

CONCLUSION

The work by Karbovskaya et al[18] strengthens the case that a brief, single-lead ECG contains sufficient information to support diabetes screening when paired with carefully designed machine-learning methods. By incorporating phenotype clustering, the authors highlight a practical strategy to confront clinical heterogeneity and improve the interpretability of model behavior across subgroups. If validated prospectively across devices and populations, phenotype-aware ECG screening could become a low-friction gateway to confirmatory testing and earlier cardiometabolic intervention, particularly in settings where laboratory screening is underutilized. The broader implication is clear: The future of digital cardiometabolic biomarkers may depend as much on thoughtful cohort and phenotype design as on algorithm choice.